PARIS, Oct. 13 /PRNewswire/ — Cellectis bioresearch, a
specialist in genome customization and subsidiary of Cellectis
(Alternext: ALCLS), today announced that it has established a US
subsidiary, Cellectis bioresearch Inc. Located at the Cambridge
Innovation Center in Cambridge, Massachusetts, Cellectis
bioresearch Inc. will be responsible for the US-wide promotion of
Cellectis bioresearch products and services.
Cellectis bioresearch’s portfolio today offers over 100 product
references, fitting the major needs for genome customization of the
life science community. These products include its cellular Genome
Positioning System (cGPS®) and cGPS® Custom targeted
integration kits, which enable the engineering of cell lines with
optimized features for drug discovery, protein production and gene
function studies.
Eric Merle will serve as Sales Director US. His strong
experience in the research tool area in the United States will be a
valuable asset in the launch of Cellectis bioresearch Inc.’s
operations. Eric Merle will be in charge of recruiting and managing
a dedicated team, covering the entire US market. He will report to
Luc Selig, VP Sales & Marketing at Cellectis bioresearch.
“Cellectis bioresearch’s goal is to make its genome
customization products the gold standard for the life sciences
community worldwide,” explains Luc Selig. “The opening of
our American subsidiary will provide us with a presence in the
largest global Life Science market and allow us to be closer to our
clients to better meet their needs.”
Together with the recently announced partnership with the
Canadian Life Science products distributor Cedarlane Inc., the
creation of Cellectis bioresearch Inc. will establish a foothold
for Cellectis bioresearch in the North American market.
About Cellectis bioresearch
Cellectis bioresearch was incorporated as a subsidiary of
Cellectis (Alternext: ALCLS) in June 2008. It provides
‘/>”/>
